These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

231 related items for PubMed ID: 19584260

  • 1. Therapeutic inhibition of the epidermal growth factor receptor in high-grade gliomas: where do we stand?
    Karpel-Massler G, Schmidt U, Unterberg A, Halatsch ME.
    Mol Cancer Res; 2009 Jul; 7(7):1000-12. PubMed ID: 19584260
    [Abstract] [Full Text] [Related]

  • 2. Epidermal growth factor receptor inhibition for the treatment of glioblastoma multiforme and other malignant brain tumours.
    Halatsch ME, Schmidt U, Behnke-Mursch J, Unterberg A, Wirtz CR.
    Cancer Treat Rev; 2006 Apr; 32(2):74-89. PubMed ID: 16488082
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Epidermal growth factor receptor inhibitors in neuro-oncology: hopes and disappointments.
    Brandes AA, Franceschi E, Tosoni A, Hegi ME, Stupp R.
    Clin Cancer Res; 2008 Feb 15; 14(4):957-60. PubMed ID: 18281526
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. New treatment strategies for malignant gliomas.
    Sathornsumetee S, Rich JN.
    Expert Rev Anticancer Ther; 2006 Jul 15; 6(7):1087-104. PubMed ID: 16831080
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Boron neutron capture therapy of EGFR or EGFRvIII positive gliomas using either boronated monoclonal antibodies or epidermal growth factor as molecular targeting agents.
    Yang W, Barth RF, Wu G, Tjarks W, Binns P, Riley K.
    Appl Radiat Isot; 2009 Jul 15; 67(7-8 Suppl):S328-31. PubMed ID: 19467880
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. HER1/EGFR inhibitor-associated rash: future directions for management and investigation outcomes from the HER1/EGFR inhibitor rash management forum.
    Pérez-Soler R, Delord JP, Halpern A, Kelly K, Krueger J, Sureda BM, von Pawel J, Temel J, Siena S, Soulières D, Saltz L, Leyden J.
    Oncologist; 2005 May 15; 10(5):345-56. PubMed ID: 15851793
    [Abstract] [Full Text] [Related]

  • 17. Molecular neuro-oncology and development of targeted therapeutic strategies for brain tumors. Part 1: Growth factor and Ras signaling pathways.
    Newton HB.
    Expert Rev Anticancer Ther; 2003 Oct 15; 3(5):595-614. PubMed ID: 14599084
    [Abstract] [Full Text] [Related]

  • 18. Small molecule inhibitors in children with malignant gliomas.
    Herrington B, Kieran MW.
    Pediatr Blood Cancer; 2009 Sep 15; 53(3):312-7. PubMed ID: 19434732
    [Abstract] [Full Text] [Related]

  • 19. Pilot study of the combination of EGFR and mTOR inhibitors in recurrent malignant gliomas.
    Doherty L, Gigas DC, Kesari S, Drappatz J, Kim R, Zimmerman J, Ostrowsky L, Wen PY.
    Neurology; 2006 Jul 11; 67(1):156-8. PubMed ID: 16832099
    [Abstract] [Full Text] [Related]

  • 20. Epidermal growth factor receptor - mediated signal transduction in the development and therapy of gliomas.
    Nicholas MK, Lukas RV, Jafri NF, Faoro L, Salgia R.
    Clin Cancer Res; 2006 Dec 15; 12(24):7261-70. PubMed ID: 17189397
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.